Ascendis Pharma (ASND) Prices 2.5M ADS Offering at $160/sh

Go back to Ascendis Pharma (ASND) Prices 2.5M ADS Offering at $160/sh

Pre-Open Stock Movers 09/01: (ABVC) (PLAN) (BLCM) Higher; (LCID) (NIO) (ASND) Lower (more...)

September 1, 2021 9:22 AM EDT

Pre-Open Stock Movers:

ABVC BioPharma, Inc. (NASDAQ: ABVC) 45% HIGHER; filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD). The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). PDC-1421 is the active ingredient for both the companys MDD and ADHD drugs.

Lucid Group (NASDAQ: LCID) 21.8% LOWER; lock-up expires.

Anaplan, Inc. (NYSE:... More

After-Hours Stock Movers 08/31: (PLAN) (PVH) (AMBA) Higher; (CRWD) (ASND) Lower (more...)

August 31, 2021 5:57 PM EDT

After-Hours Stock Movers:

Anaplan, Inc. (NYSE: PLAN) 14.5% HIGHER; reported Q2 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $144.3 million versus the consensus estimate of $133.99 million. Anaplan, Inc. sees FY2022 revenue of $571.5-573.5 million, versus the consensus of $558 million.

PVH Corp. (NYSE: PVH) 8% HIGHER; reported Q2 EPS of $2.72, $1.52 better than the analyst estimate of $1.20. Revenue for the quarter came in at $2.31 billion versus the consensus estimate of $2.14 billion. PVH... More

Ascendis Pharma (ASND) to Offer $400M in Common Stock

August 31, 2021 4:01 PM EDT

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced that it has commenced an underwritten public offering of $400,000,000 of American Depositary Shares (ADSs), each of... More